WO2008056117A1 - Appareil de détection - Google Patents

Appareil de détection Download PDF

Info

Publication number
WO2008056117A1
WO2008056117A1 PCT/GB2007/004211 GB2007004211W WO2008056117A1 WO 2008056117 A1 WO2008056117 A1 WO 2008056117A1 GB 2007004211 W GB2007004211 W GB 2007004211W WO 2008056117 A1 WO2008056117 A1 WO 2008056117A1
Authority
WO
WIPO (PCT)
Prior art keywords
alcohol
blood
matrix
test
observation zone
Prior art date
Application number
PCT/GB2007/004211
Other languages
English (en)
Inventor
James Gordon Campbell
Robin Touquet
Original Assignee
James Gordon Campbell
Robin Touquet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by James Gordon Campbell, Robin Touquet filed Critical James Gordon Campbell
Priority to EP07824447A priority Critical patent/EP2126108A1/fr
Publication of WO2008056117A1 publication Critical patent/WO2008056117A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/98—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving alcohol, e.g. ethanol in breath
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G01N33/521—Single-layer analytical elements
    • G01N33/523—Single-layer analytical elements the element being adapted for a specific analyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90206—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)

Definitions

  • the present invention relates to a diagnostic device for testing blood to determine the concentration of blood ethyl alcohol.
  • Alcohol is the most common drug of abuse and it is employed almost universally worldwide recreationally, frequently to excess and it is often abused and consumed in quantities that cause inebriation, intoxication, and loss of control. It is frequently associated with injuries requiring a hospital visit.
  • a raised blood alcohol level is definitive proof of a patient's vulnerability both in immediate management, e.g. of the airway, but also later; for identifying the dependent drinker with diminished immunity and prolonged healing rates; chronic alcohol misuse affects every body system and organ.
  • chronic alcohol misuse affects every body system and organ.
  • the opportunity of using the Teachable Moment' to effect change will be lost particularly if test confirmation of an alcohol related issue is delayed.
  • 'Clinical Inertia' is a problem, for it is all too easy for staff to forget to later ask about alcohol misuse when the patient has recovered sufficiently to be on the hospital ward.
  • a further problem relates to the dependent drinker who has developed tolerance and so may appear sober. Therefore accurate clinical assessment of the blood level of alcohol has hitherto been neither easy nor accurate.
  • the periodicity from when, and over what time, the ED presenting patient drank alcohol, its rate of absorption and how quickly the alcohol is metabolised are all very variable. However in the immediacy of presentation to the ED it would be logistically easiest to immediately obtain the blood alcohol by near patient testing.
  • Test strips or sticks are also available which are immersed in a sample of urine or saliva, and which include an indicator which changes colour in response to the presence of alcohol and these are well known. These test strips and sticks include, for example, litmus or other indicator papers for determining the pH of solutions, as well as sophisticated test devices for detecting clinically significant substances in biological fluids. Examples include glucose or protein in blood or urine samples, ketone in urine, and alcohol in saliva.
  • test strips covering both their chemistry and also techniques of manufacture and use may be found for example in U.S. Pat. Nos. 4,361 ,648 and 4,362,697. These patented schemes are concerned with testing a wide variety of body fluids for cholesterol, glucose and others, and include the suggestion of peroxidase and peroxidase-like substances as catalysts in promoting the colour change reaction on an indicator. Many of the techniques disclosed in these patents are limited to laboratory environments and require complicated instruments or complex calibration systems. Illustrative of rapid test techniques is U.S. Pat. No. US2003232321 wherein a test strip is treated to detect glucose in blood in a finger prick format.
  • an apparatus for detecting alcohol consisting of an impregnated material which produces a reaction resulting in a colour change in an observation zone in the presence of alcohol, with detection capability of less than 0.02% alcohol and greater than 0.5% such that the level of intoxication may be determined without the addition of any other reactant to a reaction zone other than those in the device and a liquid such as blood to be tested.
  • a test apparatus for alcohol comprising a matrix having an observation zone subject to a colour change dependent upon the presence of alcohol, the observation zone having an embedded reactant to alcohol to provide the colour change and the matrix arranged to regulate presentation of a test liquid to the observation zone.
  • the embedded reactant comprises an alcohol oxidase and tetramethyl benzidine.
  • the matrix incorporates a membrane.
  • the membrane comprises a fibreglass and/or non porous material.
  • the membrane incorporates cellulous fibres and/or fine fibreglass fibres. Possibly, the membrane acts as filter.
  • the matrix is supported by a fibre based card or plastic substrate or high density polystyrene substrate in order to support the matrix in use.
  • the matrix is designed to receive the test liquid in order to deliver a regulated rate of test liquid to the observation zone for reaction with the embedded reactant.
  • the matrix is arranged to present the test liquid by separation of a proportion of the test liquid for reaction with the embedded reactant.
  • the test liquid comprises blood.
  • the matrix is arranged to act as a filter for the blood to present substantially only plasma to the observation zone.
  • the embedded reactant gives a colour change visible to the naked eye.
  • the observation zone may be associated with an automatic reader device to determine the extent of colour change indicative of the proportion of alcohol within the test liquid.
  • the colour change occurs in the range 450 - 510 nano metres.
  • the matrix has an opaque or low reflectivity backing.
  • FIG. 1 shows a schematic arrangement of an embodiment of the test device.
  • FIG. 2 shows a schematic arrangement of a second embodiment of the test device.
  • FIG. 3 shows a schematic arrangement of a third embodiment of the test device.
  • the blood sample is a venous sample and invariably is obtained by a medical practitioner and is subject to strict chain of custody regulations. This approach is cumbersome and involves a time delay along with patient resistance in view of the legal consequences. A rapid broadly indicative test would be beneficial in order to take advantage of the 'teaching' moments.
  • Blood alcohol determination as described by the present invention requires the following steps.
  • Alcohol oxidase procured from suppliers such as Sigma Aldrich is dissolved in water with a suitable buffer such as sodium phosphate giving around pH 7 and peroxidase with a wetting agent such as Glyceryl laurate is used to soak cellulose membrane which is then allowed to dry.
  • a second solution of tetramethylbenzidine procured from suppliers such as Sigma Adrich dissolved in an organic solvent such as methyl chloride or xylene (m- dimethylbenzene) at around 15mg/ml is prepared and the paper is dipped into this solution and allowed to dry. This membrane is incorporated into a test strip as described elsewhere.
  • a small quantity of blood preferably a finger-prick sample of blood consisting of one drop is produced preferably by a small fingertip lancet device capable of painlessly piercing the skin and indeed this system is widely adopted routinely in hospitals using proprietary devices not included in this patent application.
  • the alcohol test device is a carrier housing the reaction membrane as a matrix which holds the enzymatic chemistry previously described on which preferably separation of the erythrocytes (red blood cells) from the plasma occurs, and colorimetric enzymatic chemistry reacts to form a coloured product which is read by the opto-electronic instrumentation or crudely by the naked eye.
  • the detection system comprises a test paper, strip or bibulous member or tube or other element carrying the technology for detecting blood alcohol, suitable for use on its own and read visually or used with a reader consisting of an opto-electronic measuring and preferably data logging system.
  • the identification system is suitable for use in all circumstances where the detection of blood alcohol is desirable or necessary, having a detection level suitable for detection of alcohol at all typical levels in human whole blood. It is also suitable for detecting alcohol in other bodily fluids for example plasma, serum or saliva and in foodstuffs and liquids.
  • the apparatus may be, but is not restricted to, application via a number of embodiments such as a strip element dipped into the solution or the solution may be applied to the element from a finger prick system or using a dropper, or the elements may be contained within a casing, cassette or apparatus, or sandwich of membranes serving a similar function.
  • the present invention optionally includes a facility to simultaneously or sequentially detect blood alcohol and blood glucose on the same sample.
  • the accuracy to the present alcohol determination is proportional to the concentration, and whilst the present method will be highly reliable at zero concentration, (it is important to determine if a patient has been drinking at all recently) accuracy will be within about 5% for levels above 10mgs% making the procedure unsuitable for judicial considerations.
  • the test acts as an indicator to medical treatments and determination as well as with regard to the 'teach' moment as discussed above.
  • Blood alcohol determination as described by the present invention requires alcohol oxidase which is available from many suppliers (e.g. Sigma Aldrich) and tetramethylbenzidine (also available from Sigma Aldrich) impregnated onto a matrix membrane in the form of a sandwich.
  • alcohol oxidase which is available from many suppliers (e.g. Sigma Aldrich) and tetramethylbenzidine (also available from Sigma Aldrich) impregnated onto a matrix membrane in the form of a sandwich.
  • the oxidation of tetramethyl benzidine yields a component with an absorbance maximum at 450 nm.
  • ethanol is detected by one of several existing proprietary systems.
  • One such method utilizes a system whereby alcohol is transformed into acetaldehyde by the action of alcohol dehydrogenase or oxidase, with this reaction, in turn, reducing an NAD indicator to its NADH form.
  • the extent of the reaction is determined by ultraviolet colorimetry providing the ultimate indication of alcohol content in the body fluid tested.
  • Such an arrangement while well suited to laboratory conditions, is poorly suited to the determining of the alcohol content of an emergency room admission because it is too time consuming for the results to be of value.
  • Alcohol oxidase is an enzyme also found in the human liver where it functions to catalyze the oxidation of alcohol in the same-reaction employed in the current patent. This enzyme is also employed in substantially the same way in the scheme disclosed in U.S. Pat. No. 3,493,467 but this patented arrangement is rather complex and is limited to a laboratory environment.
  • Alcohol oxidase is available from many suppliers (e.g. Sigma Aldrich) and the reaction to produce a coloured substrate reaction is commonly known and forms one of the routine tests carried out in pathology.
  • alcohol is oxidized to acetaldehyde (ethanal) and hydrogen peroxide which is used to react with a chromochemical such as tetramethylbenzidine (Sigma Aldrich).
  • a chromochemical such as tetramethylbenzidine (Sigma Aldrich).
  • the two electron oxidation of tetramethylbenzidine yields a component with an absorbance maximum at around 450 nm.
  • Recent drinking most particularly in the intervening period of some fifteen minutes from the time the patient was drinking alcohol to the time the patient is admitted to accident and emergency will produce abnormally high levels of salivary alcohol compared to the quantity of alcohol in his or her body.
  • abnormally high levels of alcohol such as is the current trend in Germany for binge drinking
  • potentially vast quantities of alcohol will reside in the stomach still to be absorbed but the salivary alcohol will be abnormally and dangerously underestimated because the doctor in attendance will be unaware of the danger to the patient that is to follow.
  • Simple saliva alcohol test strips are of little value here because they have a poor colour response, frequently have to be read in less than favourable lighting conditions and cannot give the sensitivity required to measure rising alcohol levels that may be inferred, but with no way of verifying by a doctor under the constraints of an accident and emergency situation.
  • Alcohol levels may also be detected using urine but this system of analysis requires complicated laboratory instruments and there is questionable value in using urine for this purpose because urine entering the bladder has an ever-reducing level of alcohol and each voiding of the bladder represents an average value of alcohol from the time of the previous voiding to the time of the current voiding but these times are rarely noted.
  • Absolute accuracy of blood alcohol level result is not necessary and in any case is a futile activity because the blood level will not be steady state and will either be decreasing (because the patient is metabolizing previous drinking episodes) or else increasing (because the donor is absorbing recently consumed alcohol from the gut). It will be appreciated by those experienced in the art that neither of these situations will yield a satisfactory saliva alcohol reading. What is more essential is a rapid system for detecting the approximate alcohol level in a blood sample with a reasonable test-to-test reproducibility for that particular batch of test device. This is because blood alcohol correlates accurately with the effect of alcohol on the brain and hence on the limbic system and neurological functions.
  • What is more essential is a rapid system for detecting the approximate alcohol level in a blood sample with a reasonable test accuracy, and to test reproducibility for that particular batch of test devices so that a patient's progress may be monitored reliably.
  • carrier (2) made from a suitable substrate such as fibre based card, plastic such as PVC or high density polystyrene, supports a matrix membrane (14) made from fibreglass or other non-porous material, which is co-joined onto membrane (22) consisting of cellulose or fine glass fibre suitable for retaining and filtering out red blood cells so that substantially only plasma is transferred by capillary action onto the membrane pad (31) on which it is co-joined for observation.
  • a suitable substrate such as fibre based card, plastic such as PVC or high density polystyrene
  • membrane (22) consisting of cellulose or fine glass fibre suitable for retaining and filtering out red blood cells so that substantially only plasma is transferred by capillary action onto the membrane pad (31) on which it is co-joined for observation.
  • the reaction pad (31) is made from nitrocellulose or similar bibulous material and houses a reaction zone (34) of alcohol oxidase and tetramethylbenzidine in the manner utilised by, for example, Aeon laboratories et al, 4108 Sorrento
  • This reaction zone (34) is also an observation zone viewed to provide an indication of alcohol level by a noticeable colour change.
  • this embodiment has the following purpose.
  • a blood sample such as that from a finger prick is placed at some point on the fibreglass membrane (14) and the blood sample travels along the pad by capillary action by virtue of the fact that fibreglass has numerous fibres that aid capillary action whilst at the same time having little capacity to soak up and absorb the blood, thereby providing maximum volume for the reaction to take place with the minimum of blood.
  • the fibreglass membrane is co-joined to membrane (22) having the capacity to filter out red blood cells and allowing plasma only to spill over by capillary action onto the co-joined reaction membrane (31) containing reactive medium for detecting the concentration of alcohol. Excess plasma that is available from the sample may be absorbed in the co-joined pad (42).
  • the test strip may be read visually for blood alcohol content or else the strip may be placed in an automatic reader such as the SureScreen Reader available from SureScreen Diagnostics Ltd, 1 Prime Parkway, Derby DE1 3QB England.
  • This reader displays the result of blood alcohol from scanning and establishing the density of the colorimetric reaction on the treated reaction zone of the test strip, preferably reading the degree of reaction at around 450 - 510 nm wavelength.
  • the membranes may be placed in a sandwich array as follows.
  • Inert mask (24) made from printed plastic perforated to allow the blood sample to pass and optionally carrying instructions or arrows showing the correct way to insert the test in a reader, is attached to optional membrane (15) made from material such as fibreglass or coarse nitrocellulose carrier designed to transfer a spot of blood from a finger prick through to membrane (18) consisting of cellulose or fine glass fibre suitable for retaining and filtering out red blood cells so that plasma is transferred by capillary action onto the membrane pad (16) made from nitrocellulose or similar bibulous material housing a reaction zone (21) of alcohol oxidase and tetramethylbenzidine in the manner utilised by Aeon laboratories et al.
  • a carrier such as PVC or high density polyethylene with a perforation suitable for the result of the test to be read from below through the perforation, and preferably backed by a black or low-reflectivity coating on a strip applied to the back of the carrier for the purpose of reducing the reflectance of the carrier onto the reading device in order to optimise the result in an automatic reader.
  • the sandwich may be modified such that red blood cells are not filtered out but are incorporated into the liquid being tested, in which membrane (18) may be optionally omitted, the result then consisting of a colour change notwithstanding the masking presence of red cells which nevertheless produces a result suitable for an optoelectronic detection device to read the result.
  • the second and third embodiments described above are suitable for insertion into a reading device consisting of a light emitting diode or similar preferably operating at wavelengths between 450 and 510 nm and an optoelectronic detection device such as a charge coupled camera, light detection diode or other suitable detector capable of reading absorbance under these same lighting conditions in order to produce an automated reading of blood alcohol.
  • a reading device consisting of a light emitting diode or similar preferably operating at wavelengths between 450 and 510 nm and an optoelectronic detection device such as a charge coupled camera, light detection diode or other suitable detector capable of reading absorbance under these same lighting conditions in order to produce an automated reading of blood alcohol.
  • the reader has a liquid crystal display to enable the user to read the results, a meter sensor area and a battery compartment.
  • the meter has an on-off button, a memory recall button to recall previous results and a code adjustment button for calibration which may act as a function button for other operations.
  • the meter will incorporate a data port for the results to be downloaded.
  • the meter will have a Bluetooth function to automatically download the results to the patient's records or a central database.
  • the meter is set up using a control solution having a known concentration of alcohol in a suitable solution, which preferably is coloured.
  • the meter produces a result from one drop of blood produced by a finger prick test using a lancet.
  • the respective components may be arranged in other formats suitable for automated instrumentation such as tubes, panels with other tests, and the like.
  • the detection system may for example comprise a test paper, strip or bibulous member or tube or other element.
  • the proposed device application is not restricted to blood from an ED or RR admissions patient and it may for example be applied to living or dead patients, to finger prick or whole bulk blood, serum or plasma, from medical patients, alcohol units, or home applications for monitoring of alcohol abuse, or for various other applications such as monitoring of the performance of personnel working in hazardous environments, for example.
  • the scope of application of the device includes any application where alcohol detection is desirable including the screening of foodstuffs for contamination, whereby for example yeast attack of fruit or fruit extracts could be detected by the onset of fermentation of alcohols; nor is the invention limited to the aforementioned applications.
  • blood alcohol tests are incorporated together with glucose monitoring by the use of multiple chemistries or else separate reaction areas on the same embodiment, whereby blood alcohol level may be read at any suitable wavelength such as 450 - 510 nm and blood glucose may be read at an appropriate wavelength such as 560 nm.
  • the present invention may be advantageous because blood alcohol accurately represents the state of the patient because it is free from the disadvantages of saliva, breath or urine which can be vastly different from the level of alcohol in the brain and other organs for reasons discussed previously.
  • the present invention may be advantageous because the level of blood alcohol will be obtained from any patient whether conscious, incapacitated, comatose, injured, cooperative or non co-operative via a simple finger prick blood sample.
  • the present invention may be advantageous because the medical profession prefer to rely on blood alcohol levels over any other medium such as breath or saliva because blood alcohol relates directly to the effects of alcohol on the brain and other organs.
  • the present invention may be advantageous because the medical profession routinely obtain and handle blood samples for a range of other medical tests and are conversant and readily prepared in their areas such as Ed's for the taking and handling of blood samples.
  • the present invention may be advantageous because the quantity of blood required is very small being typically one drop, and this quantity is readily obtained by a number of medical lancet devices already used routinely in healthcare, such devices requiring little or no training and virtually painless in use.
  • the present invention may be advantageous because blood alcohol measurements can easily be repeated from time to time as necessary to monitor alcohol levels and avoid the risk of alcohol poisoning from alcohol still remaining in the stomach of an incapacitated patient.
  • the present invention may be advantageous because the test device will also detect the simpler homologue methanol (from methylated spirit) which is toxic and which is often implicated in alcoholics living on the street who frequently require medical attention in ED's.
  • the present invention may be advantageous because the blood alcohol level may be incorporated into other devices separately or simultaneously.
  • the present invention allows the simultaneous analysis of blood alcohol and blood glucose in one operation and one machine to the benefit of the clinician and the patient.
  • the reagents and matrix configured to provide the desired colour changes necessary for each analysis as noted by the naked eye are provided in one test assembly or a machine reader for both tests provided so that the results are given together for convenience.
  • the present invention may be advantageous because the system is suitable for reading in an automatic reader which provides results from illumination at 450-510 nm which optimises the accuracy of the result.
  • the present invention may be advantageous because the blood alcohol result is achieved in such a way that it is unlikely to be admissible as evidence, thus preventing patients from refusing a test in case they are subjected to legal action.
  • the simultaneous analysis of blood alcohol and blood glucose in one operation may be advantageous because these results are both important and provide complementary information for the clinician in cases where hypoglycaemic symptoms can closely mimic those of someone who is inebriated or in cases where it is known that alcohol can trigger dangerously serious hypoglycaemia in those people who are susceptible, and this information determined at the same time is to the benefit of the clinician and the patient in providing treatment in the shortest timescale.
  • the present device may be used in other areas and other hospital disciplines, e.g. Gastro-enterology (including Hepatology), or for its use in General Practice or by Addiction services.
  • Gastro-enterology including Hepatology
  • Addiction services e.g. Gastro-enterology (including Hepatology)
  • the immediacy of near patient testing - facilitated by using the proposed device - will enable the practitioner to better manage their patients, as well as making practitioners more 'alcohol aware 1 so as to get their patients to contemplate change if alcohol levels are found to be high.
  • verbal consent from the alert and orientated patient the patient is taking part in the process of assessing their own blood alcohol concentrations. This will further the reality to the patient that alcohol is a drug - not just a social lubricant - and therefore provide the opportunity for excessive drinking or episodes of binge drinking - to be discussed in real time without having to wait for a laboratory test result.

Abstract

La présente invention concerne un appareil d'alcooltest, l'appareil comprenant une matrice comportant une zone d'observation subissant un changement de couleur en fonction de la présence d'alcool, ladite zone comportant un réactif à l'alcool inclus permettant le changement de couleur et la matrice étant disposée pour réguler l'introduction d'un liquide soumis à essai dans la zone observation.
PCT/GB2007/004211 2006-11-08 2007-11-05 Appareil de détection WO2008056117A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07824447A EP2126108A1 (fr) 2006-11-08 2007-11-05 Appareil de détection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0622212A GB0622212D0 (en) 2006-11-08 2006-11-08 Detection system apparatus
GB0622212.9 2006-11-08

Publications (1)

Publication Number Publication Date
WO2008056117A1 true WO2008056117A1 (fr) 2008-05-15

Family

ID=37594510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/004211 WO2008056117A1 (fr) 2006-11-08 2007-11-05 Appareil de détection

Country Status (3)

Country Link
EP (1) EP2126108A1 (fr)
GB (1) GB0622212D0 (fr)
WO (1) WO2008056117A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143601A1 (fr) 2008-05-27 2009-12-03 Zbx Corporation Membrane analytique enzymatique, dispositif et procédé de test

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786596A (en) * 1985-02-20 1988-11-22 Chem-Elec., Inc. Method of preparing a test strip for alcohol testing
EP0304304A2 (fr) * 1987-08-18 1989-02-22 Dermal Systems International Système de détection transdermique
US4962025A (en) * 1986-01-02 1990-10-09 Moldowan Mervin J Reagent alcohol test strip device
JPH034799A (ja) * 1989-06-02 1991-01-10 Nok Corp アルコール検出試験紙
US4994238A (en) * 1988-06-09 1991-02-19 Daffern George M Constant volume chemical analysis test device
US5173433A (en) * 1990-10-11 1992-12-22 Toxi-Lab Incorporated Method for chemical analysis
US20060008920A1 (en) * 2004-07-09 2006-01-12 Branan Medical Corporation Combination assay for alcohol and drugs of abuse
JP2006238851A (ja) * 2005-03-07 2006-09-14 Combi Corp タンパク質を含有する試料中のアルコールの検出方法及びアルコール検出キット
CN1837821A (zh) * 2005-03-24 2006-09-27 丁国兴 制备检测唾液酒精含量试纸的方法及该试纸

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786596A (en) * 1985-02-20 1988-11-22 Chem-Elec., Inc. Method of preparing a test strip for alcohol testing
US4962025A (en) * 1986-01-02 1990-10-09 Moldowan Mervin J Reagent alcohol test strip device
EP0304304A2 (fr) * 1987-08-18 1989-02-22 Dermal Systems International Système de détection transdermique
US4994238A (en) * 1988-06-09 1991-02-19 Daffern George M Constant volume chemical analysis test device
JPH034799A (ja) * 1989-06-02 1991-01-10 Nok Corp アルコール検出試験紙
US5173433A (en) * 1990-10-11 1992-12-22 Toxi-Lab Incorporated Method for chemical analysis
US20060008920A1 (en) * 2004-07-09 2006-01-12 Branan Medical Corporation Combination assay for alcohol and drugs of abuse
JP2006238851A (ja) * 2005-03-07 2006-09-14 Combi Corp タンパク質を含有する試料中のアルコールの検出方法及びアルコール検出キット
CN1837821A (zh) * 2005-03-24 2006-09-27 丁国兴 制备检测唾液酒精含量试纸的方法及该试纸

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143601A1 (fr) 2008-05-27 2009-12-03 Zbx Corporation Membrane analytique enzymatique, dispositif et procédé de test
EP2288720A1 (fr) * 2008-05-27 2011-03-02 ZBX Corporation Membrane analytique enzymatique, dispositif et procédé de test
EP2288720A4 (fr) * 2008-05-27 2012-03-14 Zbx Corp Membrane analytique enzymatique, dispositif et procédé de test

Also Published As

Publication number Publication date
GB0622212D0 (en) 2006-12-20
EP2126108A1 (fr) 2009-12-02

Similar Documents

Publication Publication Date Title
US5443080A (en) Integrated system for biological fluid constituent analysis
US4397956A (en) Means for monitoring the status of control of ketoacidosis-prone diabetics
RU2411001C2 (ru) Измерительный прибор с многоуровневым интерфейсом пользователя
Yamaguchi et al. Noninvasively measuring blood glucose using saliva
US6958129B2 (en) Combined assay for current glucose level and intermediate or long-term glycemic control
EP2376912B1 (fr) Procédé et appareil permettant la détermination de l'alcoolémie à partir d'un échantillon de sang
JPH04223267A (ja) 使い捨て試薬ユニット
US8551418B2 (en) System and method for repositioning a diagnostic test strip after inoculation
Friedemann et al. Chemical testing procedures for the determination of ethyl alcohol
WO1999035487A1 (fr) Procedes et appareil permettant l'analyse exacte des composants d'un fluide corporel
CA2460073A1 (fr) Systeme de bande d'essai a relief
McLean et al. Comparison of the Lactate Pro and the YSI 1500 Sport Blood Lactate Analyzers.
EP2126108A1 (fr) Appareil de détection
JP2020505606A (ja) 流体試料中のグルコース濃度を検出するための垂直流アッセイデバイス
US20030077205A1 (en) Diagnostic test optical fiber tips
MXPA05011080A (es) Dispositivo medico para monitorear niveles de fenilalanina en la sangre.
US20100297601A1 (en) Small volume and ultra speed colorimetric sensor
Burkhardt Chemical assays--new opportunities.
Keim et al. Accuracy of an Enzymatic Assay Device for Sermn Ethanol Measurement
Dubowski Analysis of ethanol in saliva
JP2631900B2 (ja) 乾式分析要素を用いた臨床検査方法
US8501111B2 (en) Small volume and fast acting optical analyte sensor
WO2024086700A1 (fr) Capture et utilisation de résultats pour dosages de diagnostic par l'intermédiaire de dispositifs de points de collecte utilisant des dispositifs mobiles
Tu Colorimetric Determination of Ethanol and Cortisol in Human Biofluids
WO2021097545A2 (fr) Système, procédé et dispositif de mesure de concentration d'un bioanalyte

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07824447

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007824447

Country of ref document: EP